梅花生物(600873.SH)業績快報:2021年度淨利升139.4%至23.51億元
格隆匯3月1日丨梅花生物(600873.SH)披露2021年度業績快報,報吿期內,公司實現營業收入228.37億元,較上年同期增長33.94%;歸屬於上市公司股東淨利潤23.51億元,較上年同期增長139.4%。淨利潤提升帶來公司基本每股收益以及淨資產收益率的大幅提升。
驅動公司收入增長的主要原因為:公司子公司吉林梅花二期味精產能釋放,味精銷量增長;蘇氨酸量價齊增,賴氨酸、黃原膠以及其他飼料產品價格上漲,主營業務收入增加。
公司利潤增長的主要原因為:報吿期,公司原材料價格較上年同期上漲,儘管主要原材料價格呈現不同程度上漲,但公司不斷提升經營管理水平、科學決策,抓住市場有利時機,主要產品味精、蘇氨酸、賴氨酸、黃原膠以及其他飼料氨基酸產品的售價上漲幅度大於原材料價格增長幅度,從而營業成本增幅小於營業收入的增幅,毛利及毛利率均較上年同期有所增加,毛利增加帶動利潤增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.